Inspire Medical price target lowered to $68 from $90 at RBC Capital

RBC Capital lowered the firm’s price target on Inspire Medical (INSP) to $68 from $90 and keeps a Sector Perform rating on the shares. The company ssued formal 2026 guidance of 4%-10% y/y, below its prior base case guide of 10%-11%, due to Inspire V coding headwinds, sending the stock down about 9%, the analyst tells investors in a research note. Guidance assumes flat y/y growth in Q1 with acceleration thereafter, which still needs to be proven out, RBC adds.